link.springer.com

Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo - Human Cell

  • ️Matushansky, Igor
  • ️Mon Aug 06 2012

Abstract

To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.

Access this article

Log in via an institution

Subscribe and save

  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Li WW, Takahashi N, Jhanwar S et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001; 7: 2908–11.

    PubMed  CAS  Google Scholar 

  2. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22: 1706–12.

    Article  PubMed  CAS  Google Scholar 

  3. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595–602.

    Article  PubMed  CAS  Google Scholar 

  4. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 corrected. J Clin Oncol 2007; 25: 2755–63.

    Article  PubMed  CAS  Google Scholar 

  5. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 2007; 12: 999–1006.

    Article  PubMed  CAS  Google Scholar 

  6. Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol Oncol Clin North Am 2005; 19: 427–49, v.

    Article  PubMed  Google Scholar 

  7. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 2004; 364: 1127–34.

    Article  PubMed  CAS  Google Scholar 

  8. Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005; 23: 964–9.

    Article  PubMed  CAS  Google Scholar 

  9. Graat HC, Witlox MA, Schagen FH et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 2006; 94: 1837–44.

    Article  PubMed  CAS  Google Scholar 

  10. Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Investig New Drugs 2007; 25: 305–12.

    Article  CAS  Google Scholar 

  11. Moneo V, Serelde BG, Fominaya J et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007; 100: 339–48.

    Article  PubMed  CAS  Google Scholar 

  12. Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117: 9.

    Article  Google Scholar 

  13. Chambers JM. Linear models. In: Chambers SJM, Hastie TJ, eds. Statistical Models. Pacific Grove, California: Wadsworth & Brooks/Cole, 1992; 96–138.

    Google Scholar 

  14. Hastie TJ, Pregibon D. Generalized linear models. In: Chambers SJM, Hastie TJ, eds. Statistical Models. Pacific Grove, California: Wadsworth & Brooks/Cole, 1992; 196–246.

    Google Scholar 

  15. Wilkinson GN, Rogers CE. Symbolic descriptions of factorial models for analysis of variance. Appl Stat 1973; 22: 392–9.

    Article  Google Scholar 

  16. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998; 83: 490–7.

    Article  PubMed  CAS  Google Scholar 

  17. Leach FS, Tokino T, Meltzer P et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231–4.

    PubMed  CAS  Google Scholar 

  18. Latres E, Drobnjak M, Pollack D et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994; 145: 345–55.

    PubMed  CAS  Google Scholar 

  19. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Med 2007; 13: 748–53.

    Article  PubMed  CAS  Google Scholar 

  20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Columbia University, New York, New York, USA

    Joslyn Mills, Tulio Matos, Elizabeth Charytonowicz, Todd Hricik, Mireia Castillo-Martin & Fabrizio Remotti

  2. Department of Orthopedics, Columbia University, New York, New York, USA

    Francis Y. Lee

  3. Division of Medical Oncology, Department of Medicine, Member, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Ave 301, 10032, New York, NY, USA

    Igor Matushansky

Authors

  1. Joslyn Mills

    You can also search for this author in PubMed Google Scholar

  2. Tulio Matos

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth Charytonowicz

    You can also search for this author in PubMed Google Scholar

  4. Todd Hricik

    You can also search for this author in PubMed Google Scholar

  5. Mireia Castillo-Martin

    You can also search for this author in PubMed Google Scholar

  6. Fabrizio Remotti

    You can also search for this author in PubMed Google Scholar

  7. Francis Y. Lee

    You can also search for this author in PubMed Google Scholar

  8. Igor Matushansky

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Igor Matushansky.

About this article

Cite this article

Mills, J., Matos, T., Charytonowicz, E. et al. Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo . Hum Cell 22, 85–93 (2009). https://doi.org/10.1111/j.1749-0774.2009.00073.x

Download citation

  • Received: 23 June 2009

  • Accepted: 21 July 2009

  • Published: 06 August 2012

  • Issue Date: December 2009

  • DOI: https://doi.org/10.1111/j.1749-0774.2009.00073.x

Key words